Search Results for: LXRX

BioHealth Business Daily (ABII, STEM, XNPT, LXRX, MIPI, LLY, GTXI, SHPGY, JAZZ)

We are seeing many key movers in the BioHealth space today.  Biotech stocks and drug stocks are often more volatile than other sectors.  Today's BioHealth Business Daily includes the key ...
Read Full Story »

Public Offering Floodgates Open Wide (CUZ, DHX, DFS, EPR, FNSR, FPO, GEL, G, GLP, HIG, IRDM, LXRX, NVAX, ORG, SATC, TTMI)

If you think you are alone in noticing that the markets have held up extremely well, you better take a look and see what managers and officers of public companies ...
Read Full Story »

Top Day Trader Alerts (BBY, BCRX, C, DNDN, ING, LXRX, YHOO)

These are this morning’s top pre-market day trader alert stocks.  We have more color and more detail on price and volume analysis linked through to each at VSInvestor.com: Best Buy ...
Read Full Story »

Lexicon New Alzheimer’s Disease Trial Dosing (LXRX)

Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) has announced that dosing has commenced in its Phase IIa clinical trial with LX6171.  This is an oral drug candidate that is implied for the ...
Read Full Story »

Lexicon Pharmaceuticals: Back From The Depths With New Investors (LXRX)

Lexicon Pharmaceuticals, Inc. (LXRX-NASDAQ) is a biotech company that many have not heard of, and those who do know it may have a painful history from it.  Anyone who got ...
Read Full Story »

What’s Left After Lexicon’s Terminated Partnership With Sanofi

Lexicon Pharmaceuticals Inc.'s (NASDAQ: LXRX) shares made a huge gain on Wednesday after the announcement that its alliance with Sanofi (NASDAQ: SNY) was terminated. The partnership was centered around the ...
Read Full Story »

Is This Lexicon Pharmaceuticals Panic Overblown?

Lexicon Pharmaceuticals Inc. (NASDAQ: LXRX) shares were absolutely crushed on Monday after it was announced that Sanofi would be ending its partnership with the firm. This decision comes after Lexicon ...
Read Full Story »

What Lexicon Pharma Could Mean for the Future of Diabetes

Lexicon Pharmaceuticals Inc. (NASDAQ: LXRX) shares jumped on Friday after the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion on the Marketing Authorization ...
Read Full Story »

Vodafone, Lexicon Pharma Slip Into Friday’s 52-Week Low Club

January 25, 2019: Here are four stocks trading with heavy volume among just 14 equities that have posted new 52-week lows by the noon hour Friday. On the New York ...
Read Full Story »

Immunomedics, Nautilus Sink Into Friday’s 52-Week Low Club

January 18, 2019: Here are four stocks trading with heavy volume among 20 equities that have posted new 52-week lows by the noon hour Friday. On the New York Stock ...
Read Full Story »

FDA Diabetes Treatment Vote to Determine the Fate of Lexicon Therapeutics?

Lexicon Pharmaceutics Inc. (NASDAQ: LXRX) shares fell on Friday after the U.S. Food and Drug Administration (FDA) voted to approve the firm’s type 1 diabetes treatment. Although the result from ...
Read Full Story »

Biopharma Companies to Watch This Week

Companies in the biotech and pharmaceutical industries are subject to a sizable amount of risk with regards to their drug candidates passing clinical trials and gaining regulatory approval. But with ...
Read Full Story »

Biopharma Companies to Watch This Week and for the Rest of June

Companies in the biotech and pharmaceutical industries are subject to a sizable amount of risk with regards to their drug candidates passing clinical trials and gaining regulatory approval. But with ...
Read Full Story »

Top Analyst Upgrades and Downgrades: AEP, American Water, BHP Billiton, Boeing, Costco, Crocs, Dollar General, McDonald’s, Ulta Beauty and More

Stocks have been volatile lately, and this Monday was looking to be a positive day despite the geopolitical uncertainty after bombing targets in Syria. The bull market may now be ...
Read Full Story »

Wedbush Makes Big Changes to Best Ideas List for October

With the third-quarter earnings reports ready to start rolling out fast and furious, many of the top analysts we follow on Wall Street are making some changes to the lists ...
Read Full Story »